{
  "id": "60234bd51cb411341a000093",
  "type": "yesno",
  "question": "Is ofatumumab effective for multiple sclerosis?",
  "ideal_answer": "Ofatumumab, a fully human anti-CD20 monoclonal antibody, is effective for relapsing forms of multiple sclerosis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33092190",
    "http://www.ncbi.nlm.nih.gov/pubmed/33107072",
    "http://www.ncbi.nlm.nih.gov/pubmed/30985372",
    "http://www.ncbi.nlm.nih.gov/pubmed/30604390",
    "http://www.ncbi.nlm.nih.gov/pubmed/29695594",
    "http://www.ncbi.nlm.nih.gov/pubmed/30539801",
    "http://www.ncbi.nlm.nih.gov/pubmed/33090003",
    "http://www.ncbi.nlm.nih.gov/pubmed/30632834",
    "http://www.ncbi.nlm.nih.gov/pubmed/24453078",
    "http://www.ncbi.nlm.nih.gov/pubmed/32757523"
  ],
  "snippets": [
    {
      "text": "Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33092190",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ofatumumab, a fully human anti-CD20 monoclonal antibody, that binds a distinct epitope, has been further investigated in phase 3 trials for relapsing forms of MS. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33092190",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion: Ofatumumab offers beneficial outcomes for RMS\u00a0by reducing relapse and disability progression risk.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090003",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, new therapies are emerging that promise more convenience and an improved safety profile (ofatumumab) or remyelinating potential with clinical improvement (opicinumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30604390",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The emerging B-cell depleting therapies, particularly anti-CD20 agents such as rituximab, ocrelizumab, as well as the fully human ofatumumab, have shown promising clinical and magnetic resonance imaging benefit.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30539801",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AREAS COVERED: In this manuscript, we review mechanisms of action, efficacy, safety, and tolerance of anti-CD20 therapies for MS, including rituximab, ocrelizumab, and ofatumumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30632834",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Another CD20 directed mAb, ofatumumab, is in phase 3. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30985372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ofatumumab offers beneficial outcomes for RMS\u00a0by reducing relapse and disability progression risk.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33090003",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: Imaging showed that all subcutaneous ofatumumab doses demonstrated efficacy (most robust: cumulative doses \u226530 mg/12 wk), with a safety profile consistent with existing ofatumumab data.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29695594",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32757523",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}